Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer

BACKGROUND: The integration of residual cancer burden (RCB) and post‐treatment Ki67 as residual proliferative cancer burden (RPCB) has been proposed as a stronger predictor of long‐term outcome in unselected patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT), as compared wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Miglietta, Federica, Dieci, Maria Vittoria, Tsvetkova, Vassilena, Griguolo, Gaia, Vernaci, Grazia, Menichetti, Alice, Faggioni, Giovanni, Giarratano, Tommaso, Mioranza, Eleonora, Genovesi, Elisa, Cumerlato, Enrico, Bottosso, Michele, Saibene, Tania, Michieletto, Silvia, Lo Mele, Marcello, Conte, Pierfranco, Guarneri, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485331/
https://www.ncbi.nlm.nih.gov/pubmed/32618068
http://dx.doi.org/10.1634/theoncologist.2020-0201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485331/
https://www.ncbi.nlm.nih.gov/pubmed/32618068
http://dx.doi.org/10.1634/theoncologist.2020-0201

Ejemplares similares